Each winter, three respiratory viruses converge on human populations, demanding separate defenses and separate acts of compliance from the public. A research team has now demonstrated that the biological engineering required to consolidate those defenses into a single injection is achievable — assembling the signature proteins of SARS-CoV-2, influenza A, and RSV onto one hollow particle that the immune system can learn from without ever facing true infection. The result, validated in mice, is less a finished answer than a proof of possibility: that the complexity of nature's threats need not a
Scientists develop single vaccine protecting against COVID, flu and RSV
One shot covering three viruses that circulate together each winter
Mark
So they've made one shot that covers three viruses. How does that actually work mechanically?
Mimi
They're using empty viral shells—think of them as tiny spheres with no genetic material inside. They engineered cells to put three different viral proteins on the surface of these shells simultaneously. One protein from COVID, one from the flu, one from RSV.
Luke
And all three proteins actually end up on the same particle? That's the engineering claim?
Mimi
Yes. They used Chinese hamster ovary cells, which are standard in vaccine manufacturing. The cells naturally assembled all three antigens together.
Mark
What does "naturally assembled" mean here? Did they have to force it?
Mimi
They designed the genes to be expressed in the same cells, and the particles self-assembled. They tested both transient expression—temporary—and stable cell lines. The stable version produced 48 milligrams per liter of antigen.
Luke
Is that a good yield? How does it compare to existing vaccine production?
Mimi
The paper doesn't provide that comparison. It's presented as a viable yield, but I can't tell you if it's competitive with current flu or COVID vaccine manufacturing without additional data.
Mark
What happened when they tested it in animals?
Mimi
Complete protection against H1N1 influenza challenge in mice. The vaccine triggered antibodies and T-cell responses against all three viruses.
Luke
Complete protection in mice is meaningful, but mice aren't humans. And they only tested against one virus—the flu strain. They didn't challenge with COVID or RSV.
Mimi
That's correct. The influenza challenge was the proof of concept. Whether it protects against the other two in humans remains unknown.
Mark
So what's the actual next step?
Mimi
Further preclinical evaluation, then human trials. The platform itself seems sound—the question now is whether it works in people and whether it can be manufactured at scale and cost.
Der Puls
- Three major respiratory viruses circulate simultaneously each winter, yet current vaccination requires separate shots, separate appointments, and separate acts of public compliance — a fragmented system straining both individuals and health infrastructure.
- The core engineering challenge — persuading three distinct viral proteins to co-assemble onto a single particle without losing their immunological identity — was the central obstacle, and researchers have now cleared it using established CHO cell manufacturing.
- A prefusogenic RSV fusion protein variant, neither wild-type nor fully stabilized, outperformed its engineered counterparts in expression and particle incorporation, an unexpected practical finding that shapes the path toward scalable production.
- Vaccinated mice mounted antibody and T-cell responses against all three pathogens, and every animal challenged with live H1N1 influenza survived infection — complete protection in preclinical testing.
- The platform now stands at the threshold between laboratory proof and human relevance, with further preclinical work and eventual clinical trials needed to confirm whether mouse immunity translates to human protection at manufacturable scale.
Each winter, three respiratory viruses converge on human populations, demanding separate defenses and separate acts of compliance from the public. A research team has now demonstrated that the biological engineering required to consolidate those defenses into a single injection is achievable — assembling the signature proteins of SARS-CoV-2, influenza A, and RSV onto one hollow particle that the immune system can learn from without ever facing true infection. The result, validated in mice, is less a finished answer than a proof of possibility: that the complexity of nature's threats need not always be met with equal complexity in our response.
Three respiratory viruses — SARS-CoV-2, influenza A, and RSV — share the same winter season and the same human airways, yet fighting them has always required separate vaccines. A research team has now engineered a single candidate that targets all three at once, built on hollow viral shells that display each pathogen's key proteins simultaneously.
The production system relies on Chinese hamster ovary cells, a well-established platform in pharmaceutical manufacturing. The researchers coaxed these cells to assemble enveloped virus-like particles carrying three proteins at once: SARS-CoV-2 spike, influenza H1, and the RSV fusion protein. Using both transient and stable gene expression, they achieved a stable cell line yielding 48 milligrams of antigen per liter — a quantity that hints at manufacturing viability. An unexpected finding shaped the RSV component: a prefusogenic form of the fusion protein, occupying an intermediate conformational state, outperformed both the natural and engineered stabilized versions in expression efficiency and particle incorporation.
In animal testing, the adjuvanted trivalent vaccine generated IgG antibodies against all three viral targets and T-cell responses against spike and fusion proteins. Crucially, the antibodies included those binding the palivizumab epitope on RSV — a neutralizing site with established clinical relevance. When challenged with live H1N1 influenza, vaccinated mice achieved complete protection.
The deeper significance is architectural. Rather than three injections, this approach offers one particle carrying three immunological lessons. Because CHO cell systems are already embedded in pharmaceutical infrastructure, the path from laboratory to clinical development may be shorter than it would be with a novel platform. What the work cannot yet answer is whether the immune responses seen in mice will hold in humans, and whether production can scale to meet global demand — questions that only further trials will resolve.
Three respiratory viruses circulate together each winter, each one capable of serious illness. A team of researchers has now engineered a single vaccine candidate that targets all three at once—SARS-CoV-2, influenza A, and respiratory syncytial virus, or RSV—using a platform that assembles the key proteins from each pathogen onto the surface of empty viral shells.
The work centers on a production method using Chinese hamster ovary cells, a workhorse system in biotechnology. The researchers designed these cells to manufacture enveloped virus-like particles—hollow structures that mimic the outer surface of real viruses but contain no genetic material and cannot cause infection. The trick was getting three different viral proteins to assemble together on the same particle: the spike protein from SARS-CoV-2, the H1 surface protein from influenza A, and the fusion protein from RSV. Using both temporary and permanent gene expression systems, they achieved what they set out to do. The stable cell line produced antigen at a concentration of 48 milligrams per liter, a yield that suggests the approach could scale for manufacturing.
When the researchers tested different versions of the RSV fusion protein, they found that a prefusogenic variant—a form that exists in an intermediate state before the protein undergoes its final conformational change—worked better than either the wild-type protein or engineered prefusion-stabilized versions. This variant showed superior expression levels and incorporated more efficiently into the particles, a practical advantage for production.
In animal studies, the adjuvanted trivalent vaccine triggered immune responses across all three targets. Mice developed IgG antibodies against the spike protein, the H1 protein, and the RSV fusion protein. The vaccine also generated T-cell responses specific to spike and fusion proteins. Notably, the antibodies produced included those targeting palivizumab-binding site II on the RSV fusion protein—a clinically validated neutralizing epitope that is known to confer protection in humans. When researchers challenged vaccinated mice with a homologous strain of H1N1 influenza, the animals showed complete protection against infection.
The significance lies not just in the result but in the platform itself. Rather than developing three separate vaccines and asking people to receive three injections, this approach consolidates the immunological targets onto a single particle. The CHO cell production system is already established in the pharmaceutical industry, which could accelerate translation from the laboratory to clinical development. The researchers note that this foundation warrants further evaluation, suggesting the next steps would involve additional preclinical work and eventually human trials to confirm that the immune responses observed in mice translate to protection in people.
The concurrent circulation of these three viruses remains a persistent public health challenge, particularly during respiratory virus season. A combined vaccine would simplify the vaccination landscape and potentially improve uptake by reducing the number of shots required. The work demonstrates that the engineering challenge—getting three distinct viral antigens to coexist on a single particle—is solvable, and that the resulting vaccine can mount a meaningful immune response. What remains to be determined is whether this laboratory success will hold up in human subjects and whether the manufacturing process can meet the scale and cost requirements of a global vaccine.
Bemerkenswerte Zitate
The formulation provided complete protection against homologous A/Puerto Rico/8/1934 (PR8; H1N1) challenge in mice, supporting further evaluation of this CHO-derived platform for combined respiratory-virus vaccination.— Study authors
Möchten Sie die ganze Geschichte?
Das Original lesen bei Nature ↗
Health & Medicine